News

Genentech announces CENTERSTONE trial data published in NEJM
Genentech, a member of Roche (RHHBY), announced that the New England Journal of Medicine has published a detailed analysis of the Phase III ...
IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | DelveInsight
DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The ...
DelveInsight Business Research, LLP: Roche's HEMLIBRA Achieves Significant Uptake Across Key Hemophilia A Markets | DelveInsight
HEMLIBRA has strong market potential due to its unique, subcutaneous prophylactic treatment for Hemophilia A, including patients with and without factor VIII inhibitors. With increasing global ...
Roche's HEMLIBRA Achieves Significant Uptake Across Key Hemophilia A Markets | DelveInsight
DelveInsight's "HEMLIBRA Market Size, Forecast, and Market Insight Report" highlights the details around HEMLIBRA, a bispecific factor IXa- and factor X-directed antibody indicated for routine ...
News-Medical.Net5d
Cancer immunotherapy effective across all ages despite immune differences
Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a study by researchers from the Johns ...